Franklin A. Neva followed by service with the US Navy at Naval Medical Research Unit-3 in Cairo, Egypt. He spent several years at Harvard University as a researcher. He became a professor at University of Pittsburgh, where he worked with Jonas Salk on a vaccine for polio. While at Pittsburgh, he also isolated ECHO 16, the virus responsible for Boston exanthem disease. This was the first description of that disease. Together with Thomas Weller, he isolated the Rubella virus in 1962. In 1964 he moved back to Harvard to head the Department of Tropical Public Health. In 1969 he joined the National Institutes
SAV001 a feasible option for an HIV vaccine. Indeed, Jonas Salk developed a therapeutic HIV vaccine in 1987, called Remune now being developed by Immune Response BioPharma, Inc., is based on the killed whole virus approach. Remune vaccine has completed over 25 clinical studies to date and showed a robust mechanism of action restoring white blood cell counts in CD4 & CD8 T cells by reducing viral load and increasing immunity. Also, a group of researchers and professionals in the field of HIV strongly advocates that the killed HIV approach must be taken to fight back the global HIV and AIDS